📣 VC round data is live. Check it out!

Bruker Valuation Multiples

Discover Bruker's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Demant, Bio-Rad Laboratories, Masimo, Baxter International and more.

Bruker Overview

About Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.


Founded

1991

HQ

United States

Employees

9.7K

Website

bruker.com

Financials (LTM)

Revenue: $4B
EBITDA: $582M

EV

$10B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bruker Financials

Bruker reported last 12-month revenue of $4B and EBITDA of $582M.

In the same LTM period, Bruker generated $2B in gross profit, $582M in EBITDA, and $298M in net income.

Revenue (LTM)


Bruker P&L

In the most recent fiscal year, Bruker reported revenue of $3B and EBITDA of $535M.

Bruker is profitable as of last fiscal year, with gross margin of 46%, EBITDA margin of 16%, and net margin of 8%.

See analyst estimates for Bruker
LTMLast FY202320242025202620272028
Revenue$4B$3B$3B$3B$3B
Gross Profit$2B$2B$2B$2B$2B
Gross Margin50%46%51%49%46%
EBITDA$582M$535M$676M$439M$303M
EBITDA Margin17%16%23%13%9%
EBIT Margin14%13%16%11%7%
Net Profit$298M$278M$427M$113M($9M)
Net Margin9%8%14%3%(0%)
Net Debt-$2B---

Financial data powered by Morningstar, Inc.

Bruker Stock Performance

Bruker has current market cap of $9B, and enterprise value of $10B.

Market Cap Evolution


Bruker's stock price is $57.31.

Bruker share price decreased by 2.7% in the last 30 days, and increased by 39.1% in the last year.

Bruker has an EPS (earnings per share) of $1.83.

See more trading valuation data for Bruker
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$10B$9B-1.9%-2.7%58.7%39.1%$1.83

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bruker Valuation Multiples

Bruker trades at 2.9x EV/Revenue multiple, and 17.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Bruker

EV / Revenue (LTM)


Bruker Financial Valuation Multiples

As of June 4, 2026, Bruker has market cap of $9B and EV of $10B.

Bruker has a P/E ratio of 29.2x.

LTMLast FY202320242025202620272028
EV/Revenue2.9x3.0x3.5x3.0x3.0x
EV/EBITDA17.6x19.2x15.2x23.4x33.9x
EV/EBIT21.5x23.7x21.0x27.1x43.5x
EV/Gross Profit5.8x6.5x6.8x6.2x6.5x
P/E29.2x31.4x20.4x77.1xn/m
EV/FCF68.8x149.8x42.2x75.5xn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bruker Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bruker Margins & Growth Rates

Bruker grew revenue by 4% and EBITDA by 20% in the last fiscal year.

In the most recent fiscal year, Bruker reported gross margin of 46%, EBITDA margin of 16%, and net margin of 8%.

See estimated margins and future growth rates for Bruker

Bruker Margins

Last FY202420252026202720282029
Gross Margin46%49%46%51%
EBITDA Margin16%13%9%18%
EBIT Margin13%11%7%15%
Net Margin8%3%(0%)9%
FCF Margin2%4%0%7%

Bruker Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%14%2%4%
Gross Profit Growth16%9%(4%)16%
EBITDA Growth20%(35%)(31%)113%
EBIT Growth25%(22%)(38%)129%
Net Profit Growth17%(74%)(108%)(3894%)
FCF Growth279%(44%)(90%)1769%

Data powered by FactSet, Inc. and Morningstar, Inc.

Bruker Operational KPIs

Bruker's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Bruker's Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bruker's Rule of X is 29% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Bruker
LTMLast FY202320242025202620272028
Rule of 4021%22%---
Bessemer Rule of X27%29%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue--25%27%-
R&D Expenses to Revenue11%12%10%11%12%
Opex to Revenue-39%35%38%39%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bruker Competitors

Bruker competitors include Demant, Bio-Rad Laboratories, Masimo, Baxter International, Insulet, Shimadzu, Globus Medical, Horiba, Glaukos and Zydus Lifesciences.

Most Bruker public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Demant3.1x3.0x13.1x12.6x
Bio-Rad Laboratories3.1x3.1x6.6x18.1x
Masimo6.0x6.2x19.7x20.4x
Baxter International1.5x1.5x7.6x7.8x
Insulet3.8x3.5x16.1x14.5x
Shimadzu1.8x1.7x10.6x10.1x
Globus Medical3.4x3.3x11.0x10.3x
Horiba2.9x2.8x14.4x13.5x

This data is available for Pro users. Sign up to see all Bruker competitors and their valuation data.

Start Free Trial

Acquisitions by Bruker

Bruker has acquired 32 companies to date.

Last acquisition by Bruker was on January 8th 2026. Bruker acquired TOFWERK for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Bruker

TOFWERK
Biocrates Life Sciences
RECIPE
Dynamic Biosensors
Description
-
Biocrates Life Sciences is an Austrian company specializing in targeted metabolomics kits for biomarker discovery and validation in precision medicine. Its MxP Quant 500 kit enables absolute quantification of over 630 metabolites across 61 pathways using LC-MS technology, supporting research in oncology, neurology, and cardiology. The platform includes automated sample preparation with the EVO kit and cloud-based MetaboAnalyst software for data processing. Innsbruck-headquartered since 1998, Biocrates serves academic labs and pharma companies worldwide, including collaborations with Roche and AstraZeneca.
RECIPE is a Munich-based manufacturer of CE-IVD certified clinical diagnostic kits for HPLC, LC-MS/MS, and photometry. The company supplies full kits, calibrators, controls, internal standards, and optimization mixes for therapeutic drug monitoring and toxicology. Established in 2005, RECIPE supports labs in over 50 countries with validated methods for immunosuppressants and vitamin D analysis.
Dynamic Biosensors is a Munich-headquartered developer of the CalliberMX system for label-free molecular interaction analysis. The platform uses multiparametric surface plasmon resonance to characterize biologics like antibodies and vaccines in real time. Founded in 2014, the company serves pharmaceutical firms such as Roche and Bayer, enabling kinetics, affinity, and concentration measurements with sub-nanomolar sensitivity. Its cartridges support high-throughput screening for drug discovery pipelines.
HQ CountrySwitzerlandAustriaGermanyGermany
HQ City
-
Innsbruck
Munich
Munich
Deal Date8 Jan 20263 Jun 202516 Apr 20252 Oct 2024
Valuationundisclosed$108M$89Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bruker acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Bruker

Bruker has invested in 9 companies to date.

Latest investment by Bruker was on September 3rd 2025. Bruker invested in Mercy BioAnalytics in their $59M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Bruker

Mercy BioAnalytics
Terrain Bio
PrognomiQ
Tome Biosciences
Description
Mercy BioAnalytics is a diagnostics company developing blood tests for early-stage cancer detection using extracellular vesicles. Its platform analyzes EV biomarkers from liquid biopsies to identify stage I tumors in lung and breast cancers. Natick-headquartered since 2018, Mercy BioAnalytics collaborates with Mayo Clinic for clinical validation and plans FDA submissions in 2024.
Terrain BioSciences is a Boston-based biotechnology firm specializing in RNA therapeutics and vaccine platforms. It employs artificial intelligence alongside proprietary lipid nanoparticle manufacturing to optimize RNA sequence design, stability, and delivery. The company collaborates with more than twelve biotech partners to improve expression levels and accelerate clinical timelines for personalized cancer vaccines and infectious disease treatments. Terrain BioSciences focuses on mRNA modalities for oncology and immunology applications.
PrognomiQ is a proteomics company generating multi-omics datasets for early disease detection. Headquartered in San Francisco, it maps proteomes alongside genomics and metabolomics to uncover biomarkers for cancer and neurodegenerative disorders. PrognomiQ's platform powered the largest human plasma proteome map published in 2023.
Tome Biosciences is a Berkeley-headquartered biotechnology firm developing CRISPR-enabled tools for precise gene insertion. The company enables large DNA payloads up to 10 kb at targeted genomic sites without double-strand breaks, supporting therapies for genetic diseases. Launched in 2023 from Harvard and Stanford alumni, Tome advances genomic medicines for liver, muscle, and eye disorders.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Boston, MA
-
San Francisco, CA
Boston, MA
Deal Date3 Sep 202512 Feb 20255 Nov 202412 Dec 2023
RoundSeries BSeedSeries DSeries A
Raised$59M$9M$34M$213M
InvestorsAvestria Ventures; BrightEdge (American Cancer Society VC unit); Bruker; Hologic; iSelect Fund; Labcorp; Mindshift Capital; Novalis LifeSciences; Perceptive Xontogeny Venture Fund; Portfolia; Sozo VenturesBrainstorm Ventures; Bruker; Hans Bishop; Hawktail Management; John Evans; John Maraganore; Josef Feldman; Magnetic Ventures; Olive Capital; Rogue Capital Partners; Uncommon DenominatoraMoon Fund; Bruker; Catalio Capital Management; Invus; SeerAlexandria Venture Investments; Andreessen Horowitz; ARCH Venture Partners; Bruker; FUJIFILM; GV; Longwood Fund; Polaris Partners
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bruker investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bruker

When was Bruker founded?Bruker was founded in 1991.
Where is Bruker headquartered?Bruker is headquartered in United States.
How many employees does Bruker have?As of today, Bruker has over 9K employees.
Who is the CEO of Bruker?Bruker's CEO is Frank H. Laukien.
Is Bruker publicly listed?Yes, Bruker is a public company listed on Nasdaq.
What is the stock symbol of Bruker?Bruker trades under BRKR ticker.
When did Bruker go public?Bruker went public in 2000.
Who are competitors of Bruker?Bruker main competitors include Demant, Bio-Rad Laboratories, Masimo, Baxter International, Insulet, Shimadzu, Globus Medical, Horiba, Glaukos, Zydus Lifesciences.
What is the current market cap of Bruker?Bruker's current market cap is $9B.
What is the current revenue of Bruker?Bruker's last 12 months revenue is $4B.
What is the current revenue growth of Bruker?Bruker revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Bruker?Current revenue multiple of Bruker is 2.9x.
What is the current EBITDA of Bruker?Bruker's last 12 months EBITDA is $582M.
What is Bruker's EBITDA margin?Bruker's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Bruker?Current EBITDA multiple of Bruker is 17.6x.
What is the current FCF of Bruker?Bruker's last 12 months FCF is $149M.
What is Bruker's FCF margin?Bruker's last 12 months FCF margin is 4%.
What is the current EV/FCF multiple of Bruker?Current FCF multiple of Bruker is 68.8x.
How many companies Bruker has acquired to date?As of June 2026, Bruker has acquired 32 companies.
What was the largest acquisition by Bruker?$940M acquisition of Elitech Group on 27th December 2023 was the largest M&A Bruker has done to date.
What companies Bruker acquired?Bruker acquired Elitech Group, Nanophoton, NanoString Technologies, Chemspeed Technologies, Biocrates Life Sciences, PhenomeX, Inscopix, RECIPE, Biognosys, Nion, and 22 other companies.
In how many companies Bruker has invested to date?As of June 2026, Bruker has invested in 9 companies.
What was the last Bruker investment?On 3rd September 2025 Bruker invested in Mercy BioAnalytics, participating in a $59M Series B round, alongside Avestria Ventures, BrightEdge (American Cancer Society VC unit), Hologic, iSelect Fund, Labcorp, Mindshift Capital, Novalis LifeSciences, Perceptive Xontogeny Venture Fund, Portfolia, and Sozo Ventures.
In what companies Bruker invested in?Bruker invested in Tome Biosciences, Mercy BioAnalytics, Haystack Oncology, PrognomiQ, Ionpath, KIYATEC, PreOmics, Terrain Bio, and Navignostics.

See public comps similar to Bruker

Lists including Bruker

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial